Neurocognitive assessment is an essential research instrument for autism spectrum disorder (ASD), as the clinical manifestations are rooted in diverse neurocognitive processes that cause variation in clinical presentation. Few instruments comprehensively capture relevant neurocognitive domains, and most require professional assessors. The Penn Computerized Neurocognitive Battery (CNB) is widely used in child and adolescent psychiatry research across cultures. This study adapted and validated the CNB for a clinical ASD cohort in Hong Kong.

In this Hong Kong version of the CNB (CNB-HK), thirteen cognitive tasks were translated and adapted, with one task for sensorimotor speed and twelve belonging to four specific domains (episodic memory, social cognition, complex cognition, and executive function). The CNB-HK was administered to 636 normal-IQ children with ASD (mean age: 8.4 years, 87.1% male) and 412 children without ASD (mean age: 8.6 years, 55.1% male). Factor structure was examined using factor analyses.

The CNB-HK had high feasibility for children with ASD, with <7% invalid data across all tasks. The original four-factor and bi-factor structures were replicated with good model fit, and partial scalar invariance was achieved between children with and without ASD. The factor scores correlated positively with estimated IQ in the ASD group. The ASD group had worse performance across all four cognitive domains and the g factor compared to the group without ASD.

The CNB-HK is a valid, multi-domain cognitive assessment tool for children with ASD in Hong Kong, offering a feasible and reliable approach for research and clinical settings.

Impulsivity is a hallmark characteristic of substance use disorders. Recently, studies have begun to explore whether increased impulsivity in substance-dependent individuals (SDIs) is associated with a greater propensity to relapse following treatment. Despite growing recognition of its multidimensional nature, however, most studies have treated impulsivity unilaterally. Accordingly, it remains unclear whether certain facets of impulsivity are more relevant to relapse than others. The aim of the current study was to examine the relationship between multiple facets of impulsivity and short-term relapse in SDIs. As a secondary aim, we explored the role of treatment retention in this relationship.

A personality-based impulsivity questionnaire (UPPS) and three neurocognitive tasks of impulsivity [stop-signal task (SST), delay discounting task (DDT) and Iowa gambling task (IGT)] were administered in a heterogeneous sample of 70 SDIs shortly following their entry in an in-patient detoxification programme. Mediation analyses were performed to explore whether the effects of impulsivity on relapse were mediated by treatment retention.

Performance on two neurocognitive indices of impulsive choice (i.e. delay discounting and impulsive decision-making) significantly predicted short-term relapse. The effects of delay discounting and impulsive decision-making on relapse propensity were mediated by treatment retention.

Neurocognitive indices of impulsivity may be more sensitive to the prediction of relapse than trait-based self-report questionnaires. Post-treatment relapse in SDIs may be reduced by targeting the processes involved in impulsive choice and by improving treatment retention in SDIs with inflated impulsivity.